EUVIMEDEUVIMED entdecken
Crossref

Targeting SDCBP2 in acute myeloid leukemia

Yan Du, Lan-Lan Li, Feihu Chen, Yan Du

Cellular Signalling · 2023

DOI: 10.1016/j.cellsig.2023.110889 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Signalling, 2023. Verfasst von Yan Du und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230001, China; The Grade 3 Pharmaceutical Chemistry L…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Natural Science Foundation of Anhui Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemia (AML) remains a biologically heterogeneous disease with high morbidity and mortality under the existing treatment strategies. Our previous study showed that E2A might be a potential therapeutic target for AML, but the underlying mechanism was unclear. Here, we found that SDCBP2 might be a target gene of E2A through RNA-seq combined ChIP-seq screening. This was also demonstrated by Co-IP experiment. Furthermore, the expression of E2A and SDCBP2 were increased in both AML cell lines and patient samples. Downregulation of SDCBP2 expression suppressed proliferation and induced differentiation of AML cells. In human xenograft mouse leukemia model, inhibiton of SDCBP2 expression delayed AML progression. Overall, the above results confirmed that SDCBP2 might be a target gene of E2A and a potential therapeutic target for AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteAnimalsHumansMiceCell DifferentiationCell LineCell Line, TumorCell ProliferationDown-RegulationSyntenins

Stichwörter der Autor:innen

Acute myeloid leukemia (AML)DifferentiationE2ASDCBP2

Substanzen

SDCBP2 protein, humanSyntenins

Autor:innen und Institutionen

  • Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230001, China; The Grade 3 Pharmaceutical Chemistry Laboratory of State Administration of Traditional Chinese Medicine, Hef…
  • School of Pharmacy, Anhui Province Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei 230022, China; Institute for Liver Disease of Anhui Medical University…

Förderung

  • Natural Science Foundation of Anhui Province

Zitieren

APA

Du, Y., Li, L. L., Chen, F., & Du, Y. (2023). Targeting SDCBP2 in acute myeloid leukemia. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2023.110889

Vancouver

Du Y, Li LL, Chen F, Du Y. Targeting SDCBP2 in acute myeloid leukemia. Cellular Signalling. 2023. doi:10.1016/j.cellsig.2023.110889

BibTeX
@article{Du2023,
  author = {Du, Yan and Li, Lan-Lan and Chen, Feihu and Du, Yan},
  title = {Targeting SDCBP2 in acute myeloid leukemia},
  journal = {Cellular Signalling},
  year = {2023},
  doi = {10.1016/j.cellsig.2023.110889}
}
Kostenlos starten →